Increased Plasma VEGF Levels in Patients with Cerebral Large Artery Disease Are Associated with Cerebral Microbleeds

Toshiyasu Ogata\textsuperscript{a} Shinya Dohgu\textsuperscript{b} Koichi Takano\textsuperscript{c} Tooru Inoue\textsuperscript{d} Hisatomi Arima\textsuperscript{e} Fuyuko Takata\textsuperscript{b} Yasufumi Kataoka\textsuperscript{b} Yoshio Tsuboi\textsuperscript{a}

\textsuperscript{a}Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan; \textsuperscript{b}Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; \textsuperscript{c}Department of Radiology, Fukuoka University, Fukuoka, Japan; \textsuperscript{d}Department of Neurosurgery, Fukuoka University, Fukuoka, Japan; \textsuperscript{e}Department of Preventive Medicine and Public Health, Fukuoka University, Fukuoka, Japan

Keywords
Vascular endothelial growth factor · Cerebral microbleeds · Cerebral atherosclerosis

Abstract
Background/Purpose: Because atherosclerotic factors and antithrombotic agents sometimes induce cerebral microbleeds (CMBs), patients with cerebral large artery disease (CLAD) tend to have more CMBs than control subjects. On the other hand, VEGF contributes to the disruption of the blood-brain barrier, and it may induce parenchymal edema and bleeding. We conducted a study to evaluate the role of vascular endothelial growth factor (VEGF) in the occurrence of CMBs in patients with CLAD.

Methods: CLAD is defined as stenosis or occlusion of either the carotid artery or the middle cerebral artery of 50% or more. We prospectively registered patients with CLAD who were hospitalized in our neurocenter. Biological backgrounds, atherosclerotic risk factors, administration of antithrombotics before hospitalization, and levels of cytokines and chemokines were evaluated. Susceptibility-weighted imaging or T2*-weighted MR angiography was used to evaluate CMBs. The Brain Observer MicroBleed Scale (BOMBS) was used for CMB assessments. Images were analyzed with regard to the presence or absence of CMBs. We also examined plasma VEGF concentrations using a commercial ELISA kit. Because more than half showed plasma VEGF levels below assay detection limits (3.2 pg/mL), the patients were dichotomized by plasma VEGF levels into two groups (above and below the detection limit). After univariate analyses, logistic regression analysis was conducted to determine the factors associated with the CMBs after adjustment for age, sex, the presence of hypertension, and administration of antithrombotic agents. A similar analysis with CMBs separated by location (cortex, subcortex, or posterior circulation) was also conducted.

Results: Sixty-six patients (71.1 ± 8.9 years, 53 males and 13 females) were included in this study. Plasma VEGF lev-
els were not correlated with age, sex, and atherosclerotic risk factors; however, patients with VEGF levels > 3.2 pg/mL tended toward more frequent CMBs (60.0 vs. 32.6%, in the presence and absence of CMBs, \( p = 0.056 \)). With regard to the location of CMBs, those in the cortex and/or at the gray-white junction were observed more frequently in the patients with VEGF levels > 3.2 pg/mL after multivariable analyses (odds ratio: 3.80; 95% confidence interval: 1.07–13.5; \( p = 0.039 \)). **Conclusions:** In patients with CLAD, elevated plasma VEGF might be associated with CMBs, especially those located in the cortex and/or at the gray-white junction.

© 2019 The Author(s) Published by S. Karger AG, Basel

**Introduction**

Cerebral large artery disease (CLAD), defined as stenosis or occlusion of the carotid artery (CA) or the middle cerebral artery (MCA), is known to be implicated in not only ischemic stroke but also cognitive impairment [1–6]. Ischemic stroke caused by CLAD leads to a decline in cognitive function; in addition, asymptomatic patients with CLAD also show reduced cognitive performance compared with control subjects [4]. A previous study indicated that in patients with isolated mild stroke there was usually no association between cognitive performance and the occurrence of ischemic stroke [6]. However, those with atherosclerosis risk factors, in addition to CLAD, may develop cognitive impairment after even mild stroke. On the other hand, atherosclerotic factors and antithrombotic agents sometimes induce cerebral microbleeds (CMBs), which may pose an increased risk of cognitive decline or cerebral hemorrhage [7, 8]. Few reports have described reliable risk factors that contribute to CMBs, although a report suggested an association between CMBs and the occurrence of ischemic stroke in patients with carotid stenosis [9].

Vascular endothelial growth factor (VEGF) is an angiogenesis factor that leads to the proliferation of vessels. VEGF is related to the development of collaterals in symptomatic patients with CLAD [10]. Because VEGF contributes to the disruption of the blood-brain barrier, it may induce parenchymal edema and bleeding [11]. Thus, it is conceivable that VEGF might exaggerate the formation of CMBs in CLAD cases.

The hypothesis of our study was that VEGF might affect the generation of CMBs in patients with CLAD.

**Materials and Methods**

CLAD is defined as stenosis or occlusion of either the CA or the MCA of 50% or more [6]. We prospectively registered patients diagnosed with CLAD who were hospitalized in our neurocenter. The degree of stenosis was measured by either CT angiography or carotid ultrasound. We excluded patients with either a modified Rankin Scale score of ≥2, or who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, dementia diagnostic criteria.

We investigated medical records for atherosclerotic risk factors including age, sex, hypertension, diabetes mellitus, hyperlipidemia, current smoking habits, and current drinking habits, according to the definitions of atherosclerotic risks [6]. Years of education and any neurological deficit occurring within 120 days were also noted. Bilateral lesions were defined when patients had CLAD ≥50% on both sides, and CLAD was categorized as right, left, or bilateral. Also, the presence of tandem lesions was determined in patients with both CA and MCA lesions on either side. Cerebral perfusion was measured by Tc-99m ECD SPECT. The SPECT scan began 5 min after the administration of 600 MBq of Tc-99m ECD, and data were collected for 20 min using a triple-head gamma camera.
Brain MRI was performed using either a 3.0-T scanner (GE Healthcare) or a 1.5-T scanner (Philips Healthcare). The sequences included noncontrast two-dimensional fluid-attenuated inversion recovery (FLAIR) images and T2*-weighted MR angiography (SWAN) on the 3.0-T scanner, while FLAIR and susceptibility-weighted imaging (SWI) was obtained using the 1.5-T scanner. In terms of white matter lesions, deep white matter hyperintensity and periventricular hyperintensity were evaluated using FLAIR. The severity of deep white matter hyperintensity and periventricular hyperintensity was stratified according to methods described by Shinohara et al. [12]. In addition, SWI or SWAN was recorded for the evaluation of CMBs. The Brain Observer MicroBleed Scale (BOMBS) was used for the assessment of CBMs [13]. With regard to the presence or absence of CMBs, the images were analyzed by a neurologist (T.O.) and a neuroradiologist (K.T.) who were blinded to the patients’ clinical characteristics. If an opinion differed between the two observers, a consensus would be built by discussions.

**Biomarker Measurements**

To evaluate the association of CMBs with VEGF, we measured plasma VEGF concentrations in the participants using a commercial ELISA kit (MILLIPLEX MAP Multiplex Assay Kit; Merck Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. In cases with acute stroke, blood samples were not collected within 14 days of stroke onset. Because the plasma VEGF levels of 39 patients were below the ELISA detection limit (VEGF = 3.2 pg/mL), the patients who participated in this study were dichotomized by VEGF plasma levels (≥3.2 or <3.2 pg/mL) for statistical assessments. Although we measured 29 cytokines and chemokines, VEGF most closely correlated with the presence of CMBs.

**Statistics**

Crude analyses were conducted to assess the differences in patients’ background characteristics, the characteristics of the vascular lesions, and imaging findings between the participant groups with or without detectable plasma levels of VEGF. The prevalence of CMBs was also compared between the two groups defined by VEGF. Logistic regression analysis was conducted to determine the factors associated with the CMBs after adjustment for age, sex, the presence of hypertension, and administration of antithrombotic agents. A similar analysis, with CMBs separated by location (cortex, subcortex, or posterior circulation), and defined by the BOMBS criteria, was also conducted [13]. These data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 22.0, and a p value of 0.05 was considered statistically significant.

**Results**

Sixty-six CLAD patients were included in this study. Table 1 shows the background characteristics, atherosclerotic risks, and characteristics of CLAD for patients with or without detectable plasma VEGF levels. Thirty-nine patients (59.1%) exhibited a plasma VEGF level below the detection limit of the assay (3.2 pg/mL), while the number of those with VEGF ≥3.2 pg/mL was 27 (40.9%). There were no significant differences in these factors between the patients with VEGF ≥3.2 pg/mL and those with VEGF <3.2 pg/mL. Fifty patients were evaluated for the presence of CMBs by means of SWI, while SWAN was conducted on 10 patients. CMBs were present in 20 patients (30.3%). Among these, the numbers of patients with posterior, deep, and lobar CMBs were 12, 13, and 15, respectively. Table 2 shows the association between plasma VEGF levels and the frequency of CMBs. The presence of CMBs tended to be associated with VEGF ≥3.2 pg/mL. Meanwhile, the frequency of detectable plasma levels
of VEGF varied depending on the region of the CMBs; namely, lobar CMBs were significantly associated with patient plasma VEGF levels ≥3.2 pg/mL.

After adjustment for age, sex, hypertension, and prescription of antithrombotic agents, plasma levels of VEGF ≥3.2 pg/mL tended to be associated with the presence of CMBs (Table 3). Variation in the location of CMBs was still observed, and an increased level of VEGF was significantly associated with lobar CMBs.

**Discussion**

This study indicated the possible association of the presence of CMBs with an increased level of VEGF in patients with CLAD. Specifically, VEGF levels ≥3.2 pg/mL were strongly associated with the presence of lobar CMBs.

---

**Table 1.** Patients’ characteristics, risks of atherosclerosis, and characteristics of CLAD

|                        | VEGF ≥3.2 pg/mL (n = 27) | VEGF <3.2 pg/mL (n = 39) | p value |
|------------------------|--------------------------|--------------------------|---------|
| Age, years             | 73 (63–78)               | 73 (66–77)               | 0.661   |
| Sex                    | 23 (85%)                 | 30 (77%)                 | 0.534   |
| Symptoms within 120 days | 9 (33%)                  | 15 (38%)                 | 0.796   |
| Hypertension           | 20 (74%)                 | 32 (82%)                 | 0.544   |
| Diabetes mellitus      | 11 (41%)                 | 18 (46%)                 | 0.802   |
| Dyslipidemia           | 17 (63%)                 | 27 (69%)                 | 0.607   |
| Smoking                | 8 (30%)                  | 9 (23%)                  | 0.578   |
| Drinking               | 11 (41%)                 | 9 (23%)                  | 0.174   |
| ICA lesion             | 25 (93%)                 | 36 (92%)                 | 1.000   |
| **Side**               |                          |                          |         |
| Left                   | 18 (67%)                 | 20 (51%)                 |         |
| Right                  | 9 (33%)                  | 19 (49%)                 | 0.311   |
| Bilateral              | 3 (11%)                  | 6 (15%)                  | 0.727   |
| Degree of stenosis, %  | 73 (61–82)               | 80 (69–90)               | 0.140   |
| CBF of MCA area of ipsilateral side, mL/100 g/min | 32.6 (31.3–33.6) | 32.6 (28.4–35.3) | 0.749 |
| CBF of MCA area of contralateral side, mL/100 g/min | 33.5 (31.2–35.7) | 33.1 (30.4–35.6) | 0.814 |

CLAD, cerebral large artery disease; VEGF, vascular endothelial growth factor; ICA, internal carotid artery; CBF, cerebral blood flow; MCA, middle cerebral artery.

**Table 2.** Association between CMBs and VEGF

|                      | VEGF ≥3.2 pg/mL (n = 27) | VEGF <3.2 pg/mL (n = 39) | p value |
|----------------------|--------------------------|--------------------------|---------|
| Presence of CMBs      |                          |                          |         |
| Certain              | 12 (44%)                 | 8 (21%)                  | 0.056   |
| CMBS at posterior fossa | 6 (22%)                 | 6 (15%)                  | 0.528   |
| Deep CMBS            | 7 (26%)                  | 6 (15%)                  | 0.353   |
| Lobar CMBS           | 10 (37%)                 | 5 (13%)                  | 0.035   |

CMBs, cerebral microbleeds; VEGF, vascular endothelial growth factor.
It is well known that VEGF induces angiogenesis. Thus, VEGF contributes to the proliferation of collateral formation in symptomatic patients [10], which aids in the enhancement of cerebral perfusion. In animal models of cerebral ischemia, however, VEGF might magnify the disruption of the blood-brain barrier, leading to edema and bleeding in the brain, which may result in the formation of CMBs [11]. This study supports the hypothesis that VEGF negatively affects brain function in patients with CLAD. Further studies may elucidate the positive and negative effects of VEGF. It is interesting to note that VEGF was significantly associated with the generation of CMBs with a lobar distribution, but not with deep CMBs or those at the posterior fossa.

That VEGF improves hypoperfusion [10] and supports the development of lobar CMBs could be explained by the possibility that VEGF exerts both positive and negative effects on lobar and leptomeningeal arteries, which follows the theory mentioned above. We sometimes encounter a large number of CMBs in the cortex of patients with amyloid angiopathy. Our findings suggest that VEGF may also play an important role in the development of amyloid angiopathy. Conversely, VEGF was not considered to be associated with deep CMBs or those located at the posterior fossa. While hypertension sometimes leads to the formation of CMBs in the deep perforating arteries, an increase in plasma VEGF may not be implicated in CMBs in these areas. These results indicate the possibility that VEGF does not influence the formation of all CMBs, and that different mechanisms for the formation of CMBs exist between lobar and deep brain regions.

There are some limitations to this study. First, the sample size was small. Second, there were a large number of patients whose plasma VEGF levels were below the detection limit of the assay (<3.2 pg/mL); thus, an accurate assessment of the VEGF concentration for these patients was not available. Further studies are required to fully elucidate the impact of plasma VEGF on CMBs.

In conclusion, the increase in plasma VEGF levels is important for the formation of collateral vessels in CLAD, especially in lobar regions. VEGF is associated with collateral formation, but these sometimes lead to the formation of CMBs.

**Acknowledgments**

We thank Dennis T. Rogers, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

### Table 3. Age- and sex-adjusted and multivariable analyses to elucidate the association between VEGF and the presence of CMBs

|                        | Sex and age | Multivariable |
|------------------------|-------------|---------------|
|                        | OR         | 95% CI        | p value | OR         | 95% CI        | p value |
| Presence of CMBs       | 3.28       | 1.07–13.86    | 0.038   | 3.13       | 0.96–10.22    | 0.059   |
| CMBs at posterior fossa| 1.59       | 0.45–5.69     | 0.47    | 1.35       | 0.36–5.06     | 0.65    |
| Deep CMBs              | 1.84       | 0.53–6.38     | 0.34    | 1.67       | 0.47–5.93     | 0.43    |
| Lobar CMBs             | 4.02       | 1.17–13.86    | 0.028   | 3.80       | 1.07–13.49    | 0.039   |

VEGF, vascular endothelial growth factor; OR, odds ratio.
Statement of Ethics

The study protocol was approved by the Ethics Committee of Fukuoka University Hospital (IRB No.: 14-1-07). Informed consent was obtained from all the patients.

Disclosure Statement

The authors declare no conflicts of interest.

Funding Sources

This work was partly supported by the clinical research foundation in Japan.

References

1. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015 Oct;386(10004):1698–706.
2. Mathiesen EB, Waterloo K, Joakimsen O, Bakke SJ, Jacobsen EA, Bønaa KH. Reduced neuropsychological test performance in asymptomatic carotid stenosis: the Tromsø Study. Neurology. 2004 Mar;62(5):695–701.
3. Johnston SC, O'Meara ES, Manolio TA, LeRoith JD, O'Leary DH, Goldstein S, et al. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Intern Med. 2004 Feb;140(4):237–47.
4. Popovic IM, Lovrencic-Huzjan A, Simundic AM, Popovic A, Seric V, Demarin V. Cognitive performance in asymptomatic patients with advanced carotid disease. Cogn Behav Neurol. 2011 Sep;24(3):145–51.
5. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002 Nov;1(7):426–36.
6. Kimura S, Ogata T, Watanabe J, Inoue T, Tsuboi Y. Does cerebral large-artery disease contribute to cognitive impairment? eNeurologicalSci. 2017 Jun;8:5–8.
7. Kirsch W, McAuley G, Holshouser B, Petersen F, Ayaz M, Vinters HV, et al. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis. 2009;17(3):599–609.
8. Wardlaw JM, Smith EE, Biessels GJ, Gordenier C, Fazekas F, Frayne R, et al.; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 Aug;12(8):822–38.
9. Saba L, Montisci R, Raz E, Sanfilippo R, Suri J, Piga M. Association between carotid artery plaque type and cerebral microbleeds. AJNR Am J Neuro Radiol. 2012 Dec;33(11):2144–50.
10. Yu F, Lu J, Li Z, Zhou X, Zeng S, Zhan Q, et al. Correlation of plasma vascular endothelial growth factor and endostatin levels with symptomatic intra- and extracranial atherosclerotic stenosis in a Chinese Han population. J Stroke Cerebrovasc Dis. 2017 May;26(5):1061–70.
11. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab. 2002 Apr;22(4):379–92.
12. Shinohara Y, Tohgi H, Hirai S, Terasaki A, Fukuchi Y, Yamaguchi T, et al. Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). J Stroke. 2007;24(2-3):202–9.
13. Cordonnier C, Potter GM, Jackson CA, Doubal F, Keir S, Sudlow CL, et al. Improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke. 2009 Jan;40(1):94–9.